"HOPE" for the liver? Mechanistic insight into the role of the renin-angiotensin system in hepatic fibrosis

Hepatology

Volumn 40, Issue 1, 2004, Pages 263-265

  Arteel, Gavin E ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA ACTIN; ANGIOTENSIN; CYTOKINE; DIPHENYLIODONIUM SALT; DNA; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOLLAGEN; PROTEIN KINASE B; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1;

BILE DUCT LIGATION; CELL MIGRATION; DNA MICROARRAY; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; NOTE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DNA BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; STELLATE CELL; WOUND HEALING;

EID: 3042741753     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20296     Document Type: Note

References (10)

1. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens 2002;16 (Suppl 2):S2-S6.
2. Hughes AD. AT(1)-signalling in vascular smooth muscle. J Renin Angiotensin Aldosterone Syst 2000;1:125-130.
3. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-2131.
4. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-155.
5. Kim KY, Rhim T, Choi I, Kim SS. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001;276:40591-40598.
6. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-1394.
7. Gujral JS, Farhood A, Bajt ML, Jaeschke H. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. HEPATOLOGY 2003;38:355-363.
8. Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, Motley ED. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology 2000;141:3120-3126.
9. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, et al. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003;98:1371-1376.
10. Tripathi D, Therapondos G, Lui HF, Johnston N, Webb DJ, Hayes PC. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol 2004;99:390-394.